Medicare Enrolled

Dr. Wei Wang, MD, PHD

Medical Oncology · San Francisco, CA
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Low-engagement
2100 WEBSTER ST, San Francisco, CA 94115
4158858600
In practice since 2005 (20 years)
NPI: 1861482853 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Wang from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Wang? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Wang

Dr. Wei Wang is a medical oncology specialist in San Francisco, CA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Wang performed 6,124 Medicare services across 431 unique beneficiaries.

Between the years covered by Open Payments, Dr. Wang received a total of $6,823 from 37 pharmaceutical and/or device companies across 251 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Wang is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice ▲ Top 22% volume in CA $6,823 industry payments

Medicare Practice Summary

Medicare Utilization ↗
6,124
Medicare services
Top 22% in CA for medical oncology
431
Unique beneficiaries
$25
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~306 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Denosumab injection (Prolia/Xgeva) 4,860 $17 $59
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
216 $103 $306
Complete blood count (CBC) with differential
An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells.
213 $8 $24
Blood draw (venipuncture)
Insertion of a needle into a vein to collect a blood sample.
188 $6 $6
Intravenous chemotherapy infusion, 1 hour or less
Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete.
152 $138 $355
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
150 $68 $218
Normal saline infusion, 250 cc
Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid.
101 $0 $10
Zoledronic acid injection, 1 mg
An injection of zoledronic acid administered at a dose of 1 mg.
73 $7 $22
Drug injection, under skin or into muscle
A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle.
71 $13 $35
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
51 $160 $427
New patient office visit, complex (60-74 min) 18 $176 $518
Prolonged office E/M service, first 15 minutes
This code is used for additional time spent by a physician beyond the maximum required time of a primary office or outpatient evaluation and management service. It is billed in 15-minute increments based on total time spent on the date of the primary service.
18 $29 $70
Intravenous infusion, 1 hour or less
Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less.
13 $58 $171
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
4.3% high complexity
81.7% medium
13.9% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$6,823
Total received (2018-2024)
Avg $975/year across 7 years
Top 43% in CA for medical oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
37
Companies
251
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,393 (79.0%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$1,198 (17.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$231 (3.4%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$1,432
2023
$912
2022
$171
2021
$374
2020
$1,928
2019
$1,214
2018
$793

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
PFIZER INC.
$269
ABBVIE INC.
$213
ARRAY BIOPHARMA INC
$191
Novartis Pharmaceuticals Corporation
$117
Coherus Biosciences Inc.
$114
AstraZeneca Pharmaceuticals LP
$104
Daiichi Sankyo Inc.
$104
Eisai Inc.
$51
Gilead Sciences, Inc.
$41
Lilly USA, LLC
$35
Stemline Therapeutics Inc.
$33
Merck Sharp & Dohme LLC
$31
GENZYME CORPORATION
$31
Ipsen Biopharmaceuticals, Inc
$30
Genentech USA, Inc.
$28
Takeda Pharmaceuticals U.S.A., Inc.
$27
Regeneron Healthcare Solutions, Inc.
$13
Top 3 companies account for 47.0% of 2024 payments
All-time payments by company (2018-2024) ›
Seagen Inc.
$1,226
PFIZER INC.
$791
E.R. Squibb & Sons, L.L.C.
$671
AstraZeneca Pharmaceuticals LP
$595
Novartis Pharmaceuticals Corporation
$461
ARRAY BIOPHARMA INC
$329
Janssen Biotech, Inc.
$279
Pharmacyclics LLC, An AbbVie Company
$222
ABBVIE INC.
$213
Exelixis Inc.
$187
Merck Sharp & Dohme Corporation
$174
Takeda Pharmaceuticals U.S.A., Inc.
$140
Lilly USA, LLC
$134
Amarin Pharma Inc.
$119
Genentech USA, Inc.
$115
Coherus Biosciences Inc.
$114
Daiichi Sankyo Inc.
$104
Taiho Oncology, Inc.
$93
Medtronic Vascular, Inc.
$86
Eisai Inc.
$78
Seattle Genetics, Inc.
$73
Gilead Sciences, Inc.
$70
GlaxoSmithKline, LLC.
$67
Merck Sharp & Dohme LLC
$62
GENZYME CORPORATION
$60
Celgene Corporation
$48
Incyte Corporation
$42
Foundation Medicine, Inc.
$38
Astellas Pharma US Inc
$38
Stemline Therapeutics Inc.
$33
Heron Therapeutics, Inc.
$33
Ipsen Biopharmaceuticals, Inc
$30
EISAI INC.
$24
Mylan Institutional Inc.
$22
Rigel Pharmaceuticals, Inc.
$21
Bayer HealthCare Pharmaceuticals Inc.
$19
Regeneron Healthcare Solutions, Inc.
$13
Top 3 companies account for 39.4% of all-time payments
Associated products mentioned in payments ›
ALUNBRIG · Alecensa · BALVERSA · BAVENCIO · BOSULIF · BRAFTOVI · Balversa · CALQUENCE · CYRAMZA · Cabometyx · DARZALEX · EMPLICITI · ENHERTU · EPKINLY · ERLEADA · Enhertu · Erleada · Evera · FOUNDATIONONE · IBRANCE · IMBRUVICA · IMFINZI · INLYTA · Imbruvica · JAKAFI · JARDIANCE · KEYTRUDA · KISQALI · LIBTAYO · LORBRENA · LUPRON DEPOT · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · MEKINIST · NINLARO · OPDIVO · Ogivri · Onivyde · Orserdu · PADCEV · PIQRAY · PLUVICTO · Revlimid · Rozlytrek · SARCLISA · SPRYCEL · SUSTOL · Stivarga · TAFINLAR · TAGRISSO · TECENTRIQ · TRUMENBA · TUKYSA · Tavalisse · Tecentriq · Udenyca · VENCLEXTA · VERZENIO · VOTRIENT · Vascepa · XALKORI · XTANDI · ZEJULA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (79%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for a medical oncology specialist in San Francisco?
Compare medical oncologists in the San Francisco area by procedure volume, costs, and industry payment transparency.
Browse medical oncologists nearby

Geographic Context

Medical oncologists within 10 mi
30
Per 100K population
3.6
County median income
$141,446
Nearest hospital
KAISER FOUNDATION HOSPITAL - SAN FRANCISCO
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Wang is a mixed practice specialist, with above-average Medicare volume (top 22% in CA), with low-engagement industry engagement, with 20 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Wang experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Wang performed 4,860 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Wang receive payments from pharmaceutical companies?
Yes. Dr. Wang received a total of $6,823 from 37 companies across 251 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Wang's costs compare to other medical oncologists in San Francisco?
Dr. Wang's average Medicare payment per service is $25. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Wang) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →